Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).


Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need exists to develop effective strategies to prevent CVD in this population.